Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
57 hedge funds and large institutions have $63.3M invested in Cascadian Therapeutics, Inc. in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 16 increasing their positions, 31 reducing their positions, and 24 closing their positions.
627% more call options, than puts
Call options by funds: $625K | Put options by funds: $86K
26% less funds holding
Funds holding: 77 → 57 (-20)
48% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 31
56% less capital invested
Capital invested by funds: $142M → $63.3M (-$79.1M)
79% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 24
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$795K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$702K |
| 3 |
Handelsbanken Fonder
Stockholm,
Sweden
|
+$543K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$497K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$221K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.91M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$1.31M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$392K |
| 4 |
CAM
ClariVest Asset Management
San Diego,
California
|
-$370K |
| 5 |
Goldman Sachs
New York
|
-$274K |
CASC Hedge Fund Activity: Q4 2016 in Review
57 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q4 2016, worth a combined $63.3M — down 56% from $142M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of CASC and 5 opened new positions — a net loss of 19 holders — while 31 trimmed existing stakes and 16 added.
The largest buyer was Anson Funds Management, adding an estimated $795K. The largest seller was BlackRock Fund Advisors, cutting an estimated $1.91M.
- 57 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q4 2016, down from 77 in Q3 2016.
- Funds reported $63.3M of Cascadian Therapeutics, Inc. stock for Q4 2016, down 56% quarter-over-quarter.
- 5 funds opened new Cascadian Therapeutics, Inc. positions in Q4 2016 and 24 closed out, a net change of -19 holders.
- The largest Cascadian Therapeutics, Inc. buyer in Q4 2016 was Anson Funds Management, an estimated $795K added.
- The largest Cascadian Therapeutics, Inc. seller in Q4 2016 was BlackRock Fund Advisors, an estimated $1.91M sold.
Based on aggregated 13F filings for Q4 2016.